Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 5, 2010, Pages 585-590

  Shimizu, Katsuhiko ^a   Nakata, Masao ^a   Hirami, Yuji ^a   Yukawa, Takuro ^a   Maeda, Ai ^a   Tanemoto, Kazuo ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Cyclooxygenese 2; Foxp3; Nonsmall cell lung cancer; Regulatory T cell

Indexed keywords

CELL MARKER; CYCLOOXYGENASE 2; PARAFFIN; TRANSCRIPTION FACTOR FOXP3;

AGED; ARTICLE; CANCER INFILTRATION; CANCER RECURRENCE; CELL SPECIFICITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOBECTOMY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY;

EID: 77951877847     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d60fd7     Document Type: Article

References (44)

1. Asamura H, Goya T, Koshiishi Y, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008;3:46-52.
2. Griswold DE, Adams JL. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Med Res Rev 1996;16:181-206.
3. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
4. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-3764.
5. Hwang D, Scollard D, Byrne J, et al. Expression cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90: 455-460.
6. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase- 2 in carcinoma of the pancreas. Clin Cancer Res 1999;5:2018-2024.
7. Ogino S, Kirkner GJ, Nosho K, et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 2008;14:8221-8227.
8. Takatori H, Natsugoe S, Okumura H, et al. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol 2008;34:397-402.
9. Peng JP, Chang HC, Hwang CF, et al. Overexpression of cyclooxygenase- 2 in nasopharyngeal carcinoma and association with lymph node metastasis. Oral Oncol 2005;41:903-908.
10. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167-1174.
11. Kim JM, Rudensky A. The role of the transcription factor Foxp3 in the development of regulatory T cells. Immunol Rev 2006;212:86-98
12. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061.
13. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with reccurence in pathologic stage l NSCLC patients. Cancer 2006;107:2866-2872.
14. Perrone G, Ruffini PA, Catalano V, et al. Intratimoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 2008;44:1875-1882.
15. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586-2593.
16. Bates GJ, FOX SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;23:5373-15370
17. Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006;12: 5423-5434.
18. Salama P, Phillips M, Grieu F, et al. Tumor-Infltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186-192.
19. Shama S, Yang SC, Zhu L, et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005;65:5211-5220.
20. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-1005.
21. Kataki A, Scheid P, Piet M, et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med 2002;140: 320-328.
22. Schumacher K, Haensch W, Roefzaad C, et al. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001;61:3932-3936.
23. Naito Y, Saito K, Shiiba K, et al. CD8+ T-cells infiltrated within cancer cell nests as a prognostic factor in humon colorectal cancer. Cancer Res 1998;58:3491-3494.
24. Woo EY, Chu CS, Goletz TJ, et al. Regulatory T CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-14672
25. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directory inhibit autologous T cell proliferation. J Immunol 2002;168:4272-4276.
26. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinomas. J Immunol 2002;169:2756-2761.
27. Sasada T, Kimura M, Yoshida M, et al. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies. Cancer 2003;98:1089-1099.
28. Okita R, Saeki T, Takashima S, et al. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 2005;14:1269-1273.
29. Ormandy LA, Hillemann T, Wedemeyer H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005;65:2457-2464.
30. Mutoh M, Watanabe K, Kitamura T, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002;62: 28-32.
31. Krysan K, Reckamp KL, Daiwadi H, et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 2005;65:6275-6281.
32. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenases regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
33. Gately S, Li WW. Multiple role of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004;31:2-11.
34. Lin MT, Lee RC, Yang PC, et al. Cyclooxygenase-2 inducing Mcl-1- dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. J Biol Chem 2001;276:48997-49002.
35. Sorokin A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des 2004;10:647-657.
36. Costa C, Soares R, Reis-Filho JS, et al. Cyclooxygenase2 expression is associated with lymph node metastasis in human breast cancer. J Clin Pathol 2002;55:429-434.
37. Huang M, Sharma S, Mao JT, et al. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 1996; 157:5512-5520.
38. Huang M, Stolina M, Sharma M, et al. Non-small cell lung cancer cyclooxygenase2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and downregulation of interleukin 12 production. Cancer Res 1998;58:1208-1216.
39. Li JF, Chu YW, Wang GM, et al. The prognostic value of peritumonal regulatory T cells and its correlation with intratumoral cyclooxygenese-2 exprssion in clear cell renal cell carcinoma. BLU Int 2008;103:399-405.
40. Shama S, Stolina M, Yang SC, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003;9: 961-968.
41. Baratelli F, Lin Y, Zhu L, et al. Prostaglandin E2 Induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 2005;175:1483-1490.
42. Mahic M, Yaqub S, Johansson CC, et al. FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 2006;177:246-254.
43. Mahic M, Yaqub S, Bryn T, et al. Differentiation of naive CD4+ T cells into CD4+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation. J Leukoc Biol 2008;83:1111-1117.
44. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008;26:848-855.